Epidemiology and Infection

Original Papers

Uptake of pneumococcal polysaccharide vaccine in at-risk populations in England and Wales 1999–2005

R. G. PEBODYa1 c1, J. HIPPISLEY-COXa2, S. HARCOURTa3, M. PRINGLEa2, M. PAINTERa4 and G. SMITHa3

a1 HPA Centre for Infections, London, UK

a2 University of Nottingham Division of Primary Care, Nottingham, UK

a3 HPA West Midlands, Birmingham, UK

a4 HPA North West, Liverpool, UK

Abstract

The UK has had a pneumococcal polysaccharide vaccination (PPV) programme for groups at higher risk of invasive disease since 1992. This paper presents data from a sample of primary-care practices (Q-RESEARCH) of PPV uptake in patients according to their risk status. Of 2·9 million registered patients in 2005, 2·1% were vaccinated with PPV in the preceding 12 months and 6·5% in the preceding 5 years. Twenty-nine per cent of the registered population fell into one or more risk groups. The proportion of each risk group vaccinated in the previous 5 years ranged from 69% (cochlear implants), 53·4% (splenic dysfunction), 36·5% (chronic heart disease), 34·7% (diabetes), 22·9% (immunosuppressed), 28·7% (chronic renal disease), 15·9% (sickle cell disease) to 12·6% (chronic respiratory disease). Uptake was lower in areas where the non-white proportion of population was >10%. In conclusion, there remain large gaps in the uptake of PPV in several high-risk populations in the United Kingdom. Effective strategies need to be developed to address these deficiencies.

(Accepted March 05 2007)

(Online publication April 20 2007)

Correspondence:

c1 Author for correspondence: Dr R. G. Pebody, Immunisation Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London, NW9 5EQ, UK. (Email: Richard.Pebody@hpa.org.uk)

Metrics